2026 Q2 - tulosraportti
96 päivää sitten
‧1 t 9 min
0,085 USD/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 3.11. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 29.7. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 28.1. | ||
2025 Q3 - tulosraportti 5.11.2025 | ||
2025 Q2 - tulosraportti 30.7.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·28.10.TEVA Q3 (3 November): Keep your eyes on the innovation engine, not just EPS 🚀 The most important thing in the upcoming earnings report is, in my opinion, not so much EPS, but rather the growth in innovative medicines. I am keeping a special eye on: 1. AUSTEDO (main growth engine) 2. Guidance for the rest of the year 3. Continued growth of UZEDY and AJOVY 4. Free Cash Flow and debt reduction If AUSTEDO continues its strong growth and management raises guidance again, I see this as the most bullish signal for the stock. The three key products grew strongly overall in the past quarter and are the very core of Teva's growth case. In short: AUSTEDO + guidance are, in my opinion, the two most important figures in the entire earnings report. The big transformation and the pipeline The entire transformation of Teva from a low-margin generics company to a high-margin biosimilar and innovation producer is extremely significant. Added to this is a very promising pipeline: • Duvakitug (Crohn's / Ulcerative colitis): Is in phase 2b and has blockbuster potential. There are strong clinical data in a market with huge commercial value. • TEV-408 (Vitiligo and celiac disease / IL-15): Has shown very promising clinical results. Teva is deliberately targeting large, underserved diseases with minimal competition and massive unmet need. • TEV-56278 (Cancer / Attenukine™ platform): Phase 1 wildcard with great potential. Based on Teva's own patented technology, which minimizes side effects. Attenukine is technically immunotherapy (targeted antibody-cytokine fusions) that boosts the immune system locally in the tumor. The project is being tested in direct combination with Merck's mega-seller Keytruda. It will be wildly positive if that project turns out well. Price target and time horizon: Late 2031 I hold Teva as a "hold stock" until approximately late 2031. The most rewarding price journey has, in my opinion, only just begun, and I am careful not to sell too early. An EPS of 5-6 USD in late 2031 is well within reach. If the P/E multiple is simultaneously rerated to 18+, then we are looking at a price of 90-120 USD. Technical Analysis (Elliott Wave & Momentum) • Weekly chart (Elliott Wave): https://stockcharts.com/sc3/ui/?s=TEVA&a=2385216334&p=W&yr=14&mn=0&dy=0&id=p65339870449 – We are presumably concluding wave III. After this comes a presumably long-lasting wave IV, which will likely be a broad, sideways, and frustrating trading range. Wave II on the chart was a short, brutal A-B-C correction, and according to Elliott's rule of alternation, wave IV will likely be a broad and time-consuming consolidation. In the concluding wave V, which will probably not arrive until some years from now, we will see true euphoria where the professionals praise the stock – but that is precisely when they distribute it to "weak hands" (us retail investors). • Momentum & Accumulation: https://stockcharts.com/sc3/ui/?s=TEVA&a=2385178384&p=W&yr=5&mn=0&dy=0&id=p95770113238 Based on the AD line and OBV line, you can clearly see that the stock is being accumulated. Additionally, there is positive momentum in the stock. Note that we have not experienced any form of euphoria in the stock yet at all. The structural tailwinds The stock is not yet included in the major US indices, but management is actively working to get Teva included in the Russell 1000/3000. Furthermore, Teva finally secured its Investment Grade status over the late summer (Moody's on 11 August, Fitch in the summer, and S&P Global on 4 September 2026), which opens doors for the really large funds. Teva's upward price journey is, in my opinion, far from over – even though there will naturally be the classic bumps along the way. What do the rest of you think ahead of the Q3 numbers?Just sitting here looking a bit at Duvakitug, and must correct the above a little, but it's only positive for TEVA: Duvakitug (Crohn's / Ulcerative colitis) has delivered strong phase 2b data and is now in ongoing phase III programs. The drug has blockbuster potential in a very large IBD market and is one of the most important value drivers in TEVA's pipeline. https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-17-11-00-00-3239014
·27.10. · MuokattuExciting news about BXCL501 out of left field. Yet another product intended for the treatment of schizophrenia sequelae- ·20.10.Two positive news about TEVA: 1) https://seekingalpha.com/news/4654551-alvotech-wins-fda-humira-biosimilar-process 2) see out to the left : UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease
·13.10.JP Morgan raises price target for Teva from 40 to 50 dollars. https://www.investing.com/news/analyst-ratings/jpmorgan-raises-teva-stock-price-target-to-50-on-weltruza-approval-93CH-4943806
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
96 päivää sitten
‧1 t 9 min
0,085 USD/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·28.10.TEVA Q3 (3 November): Keep your eyes on the innovation engine, not just EPS 🚀 The most important thing in the upcoming earnings report is, in my opinion, not so much EPS, but rather the growth in innovative medicines. I am keeping a special eye on: 1. AUSTEDO (main growth engine) 2. Guidance for the rest of the year 3. Continued growth of UZEDY and AJOVY 4. Free Cash Flow and debt reduction If AUSTEDO continues its strong growth and management raises guidance again, I see this as the most bullish signal for the stock. The three key products grew strongly overall in the past quarter and are the very core of Teva's growth case. In short: AUSTEDO + guidance are, in my opinion, the two most important figures in the entire earnings report. The big transformation and the pipeline The entire transformation of Teva from a low-margin generics company to a high-margin biosimilar and innovation producer is extremely significant. Added to this is a very promising pipeline: • Duvakitug (Crohn's / Ulcerative colitis): Is in phase 2b and has blockbuster potential. There are strong clinical data in a market with huge commercial value. • TEV-408 (Vitiligo and celiac disease / IL-15): Has shown very promising clinical results. Teva is deliberately targeting large, underserved diseases with minimal competition and massive unmet need. • TEV-56278 (Cancer / Attenukine™ platform): Phase 1 wildcard with great potential. Based on Teva's own patented technology, which minimizes side effects. Attenukine is technically immunotherapy (targeted antibody-cytokine fusions) that boosts the immune system locally in the tumor. The project is being tested in direct combination with Merck's mega-seller Keytruda. It will be wildly positive if that project turns out well. Price target and time horizon: Late 2031 I hold Teva as a "hold stock" until approximately late 2031. The most rewarding price journey has, in my opinion, only just begun, and I am careful not to sell too early. An EPS of 5-6 USD in late 2031 is well within reach. If the P/E multiple is simultaneously rerated to 18+, then we are looking at a price of 90-120 USD. Technical Analysis (Elliott Wave & Momentum) • Weekly chart (Elliott Wave): https://stockcharts.com/sc3/ui/?s=TEVA&a=2385216334&p=W&yr=14&mn=0&dy=0&id=p65339870449 – We are presumably concluding wave III. After this comes a presumably long-lasting wave IV, which will likely be a broad, sideways, and frustrating trading range. Wave II on the chart was a short, brutal A-B-C correction, and according to Elliott's rule of alternation, wave IV will likely be a broad and time-consuming consolidation. In the concluding wave V, which will probably not arrive until some years from now, we will see true euphoria where the professionals praise the stock – but that is precisely when they distribute it to "weak hands" (us retail investors). • Momentum & Accumulation: https://stockcharts.com/sc3/ui/?s=TEVA&a=2385178384&p=W&yr=5&mn=0&dy=0&id=p95770113238 Based on the AD line and OBV line, you can clearly see that the stock is being accumulated. Additionally, there is positive momentum in the stock. Note that we have not experienced any form of euphoria in the stock yet at all. The structural tailwinds The stock is not yet included in the major US indices, but management is actively working to get Teva included in the Russell 1000/3000. Furthermore, Teva finally secured its Investment Grade status over the late summer (Moody's on 11 August, Fitch in the summer, and S&P Global on 4 September 2026), which opens doors for the really large funds. Teva's upward price journey is, in my opinion, far from over – even though there will naturally be the classic bumps along the way. What do the rest of you think ahead of the Q3 numbers?Just sitting here looking a bit at Duvakitug, and must correct the above a little, but it's only positive for TEVA: Duvakitug (Crohn's / Ulcerative colitis) has delivered strong phase 2b data and is now in ongoing phase III programs. The drug has blockbuster potential in a very large IBD market and is one of the most important value drivers in TEVA's pipeline. https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-17-11-00-00-3239014
- ·27.10. · MuokattuExciting news about BXCL501 out of left field. Yet another product intended for the treatment of schizophrenia sequelae
- ·20.10.Two positive news about TEVA: 1) https://seekingalpha.com/news/4654551-alvotech-wins-fda-humira-biosimilar-process 2) see out to the left : UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease
- ·13.10.JP Morgan raises price target for Teva from 40 to 50 dollars. https://www.investing.com/news/analyst-ratings/jpmorgan-raises-teva-stock-price-target-to-50-on-weltruza-approval-93CH-4943806
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 3.11. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 29.7. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 28.1. | ||
2025 Q3 - tulosraportti 5.11.2025 | ||
2025 Q2 - tulosraportti 30.7.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
96 päivää sitten
‧1 t 9 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 3.11. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 29.7. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 28.1. | ||
2025 Q3 - tulosraportti 5.11.2025 | ||
2025 Q2 - tulosraportti 30.7.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
0,085 USD/osake
Viimeisin osinko
0,00%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·28.10.TEVA Q3 (3 November): Keep your eyes on the innovation engine, not just EPS 🚀 The most important thing in the upcoming earnings report is, in my opinion, not so much EPS, but rather the growth in innovative medicines. I am keeping a special eye on: 1. AUSTEDO (main growth engine) 2. Guidance for the rest of the year 3. Continued growth of UZEDY and AJOVY 4. Free Cash Flow and debt reduction If AUSTEDO continues its strong growth and management raises guidance again, I see this as the most bullish signal for the stock. The three key products grew strongly overall in the past quarter and are the very core of Teva's growth case. In short: AUSTEDO + guidance are, in my opinion, the two most important figures in the entire earnings report. The big transformation and the pipeline The entire transformation of Teva from a low-margin generics company to a high-margin biosimilar and innovation producer is extremely significant. Added to this is a very promising pipeline: • Duvakitug (Crohn's / Ulcerative colitis): Is in phase 2b and has blockbuster potential. There are strong clinical data in a market with huge commercial value. • TEV-408 (Vitiligo and celiac disease / IL-15): Has shown very promising clinical results. Teva is deliberately targeting large, underserved diseases with minimal competition and massive unmet need. • TEV-56278 (Cancer / Attenukine™ platform): Phase 1 wildcard with great potential. Based on Teva's own patented technology, which minimizes side effects. Attenukine is technically immunotherapy (targeted antibody-cytokine fusions) that boosts the immune system locally in the tumor. The project is being tested in direct combination with Merck's mega-seller Keytruda. It will be wildly positive if that project turns out well. Price target and time horizon: Late 2031 I hold Teva as a "hold stock" until approximately late 2031. The most rewarding price journey has, in my opinion, only just begun, and I am careful not to sell too early. An EPS of 5-6 USD in late 2031 is well within reach. If the P/E multiple is simultaneously rerated to 18+, then we are looking at a price of 90-120 USD. Technical Analysis (Elliott Wave & Momentum) • Weekly chart (Elliott Wave): https://stockcharts.com/sc3/ui/?s=TEVA&a=2385216334&p=W&yr=14&mn=0&dy=0&id=p65339870449 – We are presumably concluding wave III. After this comes a presumably long-lasting wave IV, which will likely be a broad, sideways, and frustrating trading range. Wave II on the chart was a short, brutal A-B-C correction, and according to Elliott's rule of alternation, wave IV will likely be a broad and time-consuming consolidation. In the concluding wave V, which will probably not arrive until some years from now, we will see true euphoria where the professionals praise the stock – but that is precisely when they distribute it to "weak hands" (us retail investors). • Momentum & Accumulation: https://stockcharts.com/sc3/ui/?s=TEVA&a=2385178384&p=W&yr=5&mn=0&dy=0&id=p95770113238 Based on the AD line and OBV line, you can clearly see that the stock is being accumulated. Additionally, there is positive momentum in the stock. Note that we have not experienced any form of euphoria in the stock yet at all. The structural tailwinds The stock is not yet included in the major US indices, but management is actively working to get Teva included in the Russell 1000/3000. Furthermore, Teva finally secured its Investment Grade status over the late summer (Moody's on 11 August, Fitch in the summer, and S&P Global on 4 September 2026), which opens doors for the really large funds. Teva's upward price journey is, in my opinion, far from over – even though there will naturally be the classic bumps along the way. What do the rest of you think ahead of the Q3 numbers?Just sitting here looking a bit at Duvakitug, and must correct the above a little, but it's only positive for TEVA: Duvakitug (Crohn's / Ulcerative colitis) has delivered strong phase 2b data and is now in ongoing phase III programs. The drug has blockbuster potential in a very large IBD market and is one of the most important value drivers in TEVA's pipeline. https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-17-11-00-00-3239014
- ·27.10. · MuokattuExciting news about BXCL501 out of left field. Yet another product intended for the treatment of schizophrenia sequelae
- ·20.10.Two positive news about TEVA: 1) https://seekingalpha.com/news/4654551-alvotech-wins-fda-humira-biosimilar-process 2) see out to the left : UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease
- ·13.10.JP Morgan raises price target for Teva from 40 to 50 dollars. https://www.investing.com/news/analyst-ratings/jpmorgan-raises-teva-stock-price-target-to-50-on-weltruza-approval-93CH-4943806
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt